Abstract: Ming Yu Pharmaceutical, a China-based clinical-stage biotech company, is seeking a Hong Kong Chapter 18A listing. MS, BOA, and CITIC are the joint sponsors. In our previous note, we looked at the company's core products MHB018A and MHB036C, as well as its management and investor backings. In this note, we look at the developments in the company's assets and the competitive landscape.
Interested in the full report? Get in touch with our team.